TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02068794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Given IP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Tomography and Computed Tomography Scan
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02873195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study: NCT04490993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202 in combination with Epirubicin
Description: * Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with Epirubicin
Description: * Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months
Study: NCT04300478

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sedentary Control Condition First
Description: Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
Study: NCT02873195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT03744949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil dose 0.5 ug/kg
Description: Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil dose 1 ug/kg
Description: Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil dose 1.5 ug/kg
Description: Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil dose 2 ug/kg
Description: Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Study: NCT01380769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is administered at 15mg/m2 IV every other week

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: best supportive care
Study: NCT01311336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
Study: NCT01304602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
Study: NCT02682147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxia administration study group
Description: scan completed after 5 minutes of breathing in hypoxic air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperoxia administration study group
Description: scan completed after up to 15 minutes of breathing in hyperoxic air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Study: NCT03954899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 5mg of melatonin-otc 30 minutes before sleep
Study: NCT03047577

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief intervention
Description: A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
Study: NCT01866358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraosseous infusion
Description: Using intraosseous infusion for resustation in this group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical vein infusion
Description: Using umbilical vein infusion for resustation in this group
Study: NCT03956550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: Intravenous (IV) Dose every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: Intravenous (IV) Dose every 4 weeks (Q4W)
Study: NCT03356210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
Study: NCT00391352

Intervention type: DRUG
Intervention: IFN-β-1a (Rebif®)
Description: 44 mcg Three times a week, subcutaneous injection
Study: NCT03956550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Intravenous (IV) Dose every 4 weeks (QW4)
Study: NCT03954899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 5mg of melatonin-otc 30 minutes before sleep

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 minutes before sleep
Study: NCT03837262

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring and structured education
Description: A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
Study: NCT04561076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion
Study: NCT02335138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couples HIV Testing and Counseling (CHTC, CVCT)
Description: Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
Study: NCT03954899

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 minutes before sleep
Study: NCT01100398

Intervention type: PROCEDURE
Intervention: possible liver biopsy and serum collection
Description: All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
Study: NCT04268394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT03469466

Intervention type: DIAGNOSTIC_TEST
Intervention: bedside ultrasound
Description: bedside ultrasound imaging of the lungs
Study: NCT02228317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Telemedicine consultation done by telephone or video
Study: NCT03965494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB 324 (before surgery)
Description: Given by mouth either BEFORE therapeutic conventional surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB 324 (after surgery)
Description: Given by mouth either AFTER therapeutic conventional surgery
Study: NCT04175730

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound and MRI
Description: A single subsequent ultrasound guided prostate biopsy with MRI fusion

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: A single subsequent ultrasound guided prostate biopsy
Study: NCT01270178

Intervention type: DRUG
Intervention: Entecavir
Description: film coated tablets / 0.5mg / once daily / 3 years
Study: NCT01799226

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste without triclosan
Description: this intervention will use a toothpaste without triclosan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: this intervention will use Colgate Total which contains triclosan
Study: NCT01683708

Intervention type: DIETARY_SUPPLEMENT
Intervention: Symbiotic therapy
Description: Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
Study: NCT00974649

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: self-report questionnaire
Description: validated self-report questionnaires on psychosocial determinants
Study: NCT01492790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency cholecystectomy first
Description: The intervention is an emergency cholecystectomy without prior common bile duct imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequential common bile duct imaging/cholecystectomy
Description: This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
Study: NCT02139072

Intervention type: DEVICE
Intervention: CoaguChek XS
Description: CoaguChek XS will be used to measure INR in patients with APL

Intervention type: DEVICE
Intervention: CoaguChek XS
Description: CoaguChek XS will be used to measure INR in patients with APL

Intervention type: PROCEDURE
Intervention: Standard Lab Draw
Description: Patients on warfarin for any indication other than APL will measure INR by venous lab draw

Intervention type: PROCEDURE
Intervention: Standard Lab Draw
Description: Patients on warfarin for any indication other than APL will measure INR by venous lab draw
Study: NCT04268394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study: NCT04901520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Description: High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
Study: NCT04557800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL151
Description: oral dose(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose(s)
Study: NCT00112372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: 10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
Study: NCT02436018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEI NASAL JET
Description: Oxygen is supplied through WEI NASAL JET by a manual jet ventilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway without jet ventilator
Description: Oxygen is supplied directly through WEI NASAL JET without jet ventilator
Study: NCT03010033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations).
Study: NCT00655616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Placebo
Description: Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol, Montelukast
Description: Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily
Study: NCT04108611

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hemodiafiltration with endogenous re infusion (HFR)
Description: hemodiafiltration with endogenous re infusion (HFR) for cases 2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemodiafiltration with endogenous re infusion (HFR)
Description: hemodiafiltration with endogenous re infusion (HFR) for cases 2
Study: NCT03187119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial Asthma Action Plan
Description: Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Asthma Action Plan
Description: Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
Study: NCT04901520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Training
Description: Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Training
Description: Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
Study: NCT03610841

Intervention type: DIAGNOSTIC_TEST
Intervention: preterm labor
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: preterm labor
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: healthy
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: healthy
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
Study: NCT00483405

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: cetuximab
Description: 250 mg/m2, intravenously, once per week

Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: 850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin
Description: 130 mg/m2, intravenously on Day 1 of each 21 day cycle
Study: NCT03261388

Intervention type: BEHAVIORAL
Intervention: Activity-Based Locomotor Exercise Program (ABLE)
Description: The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
Study: NCT04121702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: Implementation of a physical exercise program (PEP) with tele-monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Implementation of a physical exercise program (PEP) with tele-monitoring
Study: NCT02089594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Hyperbaric Oxygen
Description: Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
Study: NCT04567641

Intervention type: DIETARY_SUPPLEMENT
Intervention: postoperative nutrition
Description: Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.

Intervention type: DIETARY_SUPPLEMENT
Intervention: postoperative nutrition
Description: Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.